STAT3 and neoplasm: This appears to be in line with two recent studies that identified strong antitumour activity following STAT3 ASO treatment in CT26, a tumour model used in female mice.12 23 The clinical trial data did not identify such an association; however, there were only a minority of women patients enrolled on trial.